Kiniksa Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kiniksa Pharmaceuticals (KNSA).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$82Upside to Avg. PT+5.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 30, 2026	Goldman Sachs	Paul Choi	PT Raise	Buy	$75→$90
Jul 29, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$72→$107
Jul 29, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$64→$98
Jul 29, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$72→$99
Jul 29, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$60→$100
Jul 23, 2026	Goldman Sachs	Paul Choi	PT Raise	Buy	$60→$75
Jul 13, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$57→$74
Jun 29, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$59→$72
Apr 29, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$62→$64
Apr 29, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$50→$60
Apr 29, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$58→$59
Apr 29, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$53→$57
Apr 28, 2026	Jefferies	Roger Song	PT Raise	Buy	$58→$71
Apr 16, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$53→$58
Feb 25, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$50→$53
Feb 25, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$50→$53
Feb 19, 2026	Canaccord Genuity	Edward Nash	Initiate	Buy	$62
Jan 13, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$48→$50
Oct 29, 2025	Goldman Sachs	Paul Choi	PT Raise	Buy	$45→$55
Oct 17, 2025	Citigroup	Geoff Meacham	PT Raise	Buy	$45→$50

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $72 to $107.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

Canaccord Genuity analyst Edward Nash maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $64 to $98.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $72 to $99.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $100.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $75.

Benzinga Newsdesk

Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

PRO
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

PRO
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

People Also Watch

People Also Watch

Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PROJP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

PROCanaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

PROWedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

PROCitigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

PROGoldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

People Also Watch

People Also Watch

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

PRO
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

PRO
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75